Abel Hall LLC’s Aquestive Therapeutics AQST Stock Holding History

Abel Hall LLC’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,496	Closed	-$74.3K	–	823
2025 Q4	$74.3K	Buy	+11,496	New	+$71.6K	0.02%	632

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Abel Hall LLC's AQST Position: Q1 2026 in Review

Abel Hall LLC sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 11,496 shares — an estimated $74.3K sold.

Abel Hall LLC first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $74.3K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Abel Hall LLC reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
Abel Hall LLC sold 11,496 Aquestive Therapeutics shares in Q1 2026, an estimated $74.3K.
Abel Hall LLC first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
Abel Hall LLC's Aquestive Therapeutics position peaked at $74.3K in Q4 2025.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.